Multiple Myeloma Case Developed During the Use of the Teriparatide

Multiple Myeloma Case Developed During the Use of the Teriparatide

Recombinant human parathyroid hormone (1-34) (rhPTH 1-34), teriparatide, is a class of anabolic therapy for treating severe osteoporosis. Although plasma cell dyscrasias are excluded among the known side effects of teriparatide treatment, their association in the form of case reports has been report...

Full description

Bibliographic Details
Main Authors:	Zehra Erdemir, Ayşe İyiyapıcı Ünübol, Mustafa Ünübol, Esra Ercan Aktekin, İrfan Yavaşoğlu, Engin Güney
Format:	Article
Language:	English
Published:	Galenos Yayinevi 2022-04-01
Series:	Türk Osteoporoz Dergisi
Subjects:	osteoporosis teriparatide multiple myeloma
Online Access:	http://www.turkosteoporozdergisi.org/archives/archive-detail/article-preview/multiple-myeloma-case-developed-during-the-use-of-/51345

Similar Items

Teriparatide Treatment Following Osteoporotic Hip Fracture in a Male Patient with Multiple Sclerosis and Current Recommendations
by: Sibel Başaran, et al.
Published: (2015-12-01)

Teriparatide - Indications beyond osteoporosis
by: Marilyn Lee Cheng, et al.
Published: (2012-01-01)

Teriparatide as option for severe osteoporosis
by: Mara CARSOTE, et al.
Published: (2016-12-01)

Dilemmas in the diagnosis and management of osteoporosis in a patient with alkaptonuria: Successful treatment with teriparatide
by: Ismail C. Ebrahim, et al.
Published: (2022-12-01)

More than 6 Months of Teriparatide Treatment Was More Effective for Bone Union than Shorter Treatment Following Lumbar Posterolateral Fusion Surgery
by: Seiji Ohtori, et al.
Published: (2015-08-01)

Effect of Teriparatide in Postmenopausal Women with Osteoporosis
by: Masoud Shayestehazar, et al.
Published: (2018-12-01)

Treatment of osteoporosis with teriparatide: The Slovenian experience
by: Kocjan Tomaz, et al.
Published: (2021-10-01)

The role of teriparatide in sequential and combination therapy of osteoporosis
by: Christian Meier, et al.
Published: (2014-06-01)

Impressive results of teriparatide treatment of postgastrectomy osteoporosis
by: Tatjana Bačun, et al.
Published: (2011-08-01)

The Effect of Teriparatide Treatment on Spinal Deformity Index in Severe Osteoporosis
by: Fatma Gül Ülkü Demir, et al.
Published: (2019-04-01)

Acceleration of Preexisting Aortic Stenosis After Teriparatide Initiation
by: Jayachidambaram Ambalavanan, MD, et al.
Published: (2024-07-01)

Teriparatide treatment in severe osteoporosis – a controlled 10-year follow-up study
by: Georgios Kontogeorgos, et al.
Published: (2022-11-01)

USE OF TERIPARATIDE IN SURGICAL PLANNING FOR PATIENTS WITH OSTEOPOROSIS
by: RICARDO CEPEDA JORDAN, et al.
Published: (2023-10-01)

Abaloparatide exhibits greater osteoanabolic response and higher cAMP stimulation and β‐arrestin recruitment than teriparatide
by: Karim Sahbani, et al.
Published: (2019-10-01)

Changes in BMD T-score from pre-to post-treatment with biosimilar teriparatide: A single-arm, multi-center study
by: Mohsen G. Soroush, et al.
Published: (2023-06-01)

Clinical efficacy of denosumab, teriparatide, and oral bisphosphonates in the prevention of glucocorticoid-induced osteoporosis: a systematic review and meta-analysis
by: Chuanjian Yuan, et al.
Published: (2023-06-01)

Indications and adverse events of teriparatide: based on FDA adverse event reporting system (FAERS)
by: Ming-Tao Wen, et al.
Published: (2024-08-01)

Outcomes of Treatment in Patients with Severe Postmenopausal Osteoporosis: The Effects of Teriparatide Treatment on Bone Mineral Density, Back Pain and Biochemical Parameters
by: Tuba Nazlıgül, et al.
Published: (2020-04-01)

Hypercalcemic encephalopathy due to milk alkali syndrome and injection teriparatide
by: Sandeep Kharb, et al.
Published: (2012-01-01)

The Effect of Daily Teriparatide versus One-Time Annually Zoledronic Acid Administration After Transforaminal Lumbar Interbody Fusion in Osteoporotic Patients
by: Wang Z, et al.
Published: (2021-10-01)

The Russian Council of Experts for Use of the Innovative Anabolic Agent Forsteo®(Teriparatide) in the Treatment of Severe Osteoporosis
by: Olga Mikhailovna Lesnyak
Published: (2013-10-01)

Teriparatide (recombinant human parathyroid hormone 1-34) in postmenopausal women with osteoporosis: systematic review
by: Virgínia Fernandes Moça Trevisani, et al.

Response to teriparatide in Chinese patients with established osteoporosis: osteocalcin and lumbar spine bone-mineral density changes from teriparatide Phase III study
by: Lu C, et al.
Published: (2017-10-01)

Surgical outcome of atypical subtrochanteric and femoral fracture related to bisphosphonates use in osteoporotic patients with or without teriparatide treatment
by: Wen-Ling Yeh, et al.
Published: (2017-12-01)

Effect of Teriparatide on Subsequent Vertebral Fractures after Instrumented Fusion Surgery for Osteoporotic Vertebral Fractures with Neurological Deficits
by: Keishi Maruo, et al.
Published: (2019-04-01)

Analyzing the factors associated with efficacy among teriparatide treatment in postmenopausal women with osteoporosis
by: Meng Kong, et al.
Published: (2024-02-01)

Efficacy of the Combination of Teriparatide and Denosumab in the Treatment of Postmenopausal Osteoporosis: A Meta-Analysis
by: Yang Sun, et al.
Published: (2022-05-01)

Cost‐Effectiveness of Sequential Teriparatide/Alendronate Versus Alendronate‐Alone Strategies in High‐Risk Osteoporotic Women in the US: Analyzing the Impact of Generic/Biosimilar Teriparatide
by: Takahiro Mori, et al.
Published: (2019-11-01)

Teriparatide Treatment in Patients with Severe Osteoporosis: Effects on Bone Mineral Density, Biochemical Parameters, Back Pain and Quality of Life
by: Alev Çevikol, et al.
Published: (2014-08-01)

An observational study to assess back pain in patients with severe osteoporosis treated with teriparatide versus antiresorptives: An Indian subpopulation analysis
by: Harvinder Chhabra, et al.
Published: (2015-01-01)

Review of the Literature on the Impact of Teriparatide Use on Bone Healing
by: Larysa Bielecka
Published: (2025-02-01)

The Effects of Longer Use of Teriparatide on Clinical and Radiographic Outcomes after Spinal Fusion in Geriatric Patients
by: Young-Hoon Kim, et al.
Published: (2024-06-01)

Extremely elevated serum alkaline phosphatase level upon treatment with teriparatide: a case report
by: Ali Javinani, et al.
Published: (2020-07-01)

Normocalcemic primary hyperparathyroidism in a patient with severe osteoporosis receiving teriparatide
by: Vishal Gupta
Published: (2013-01-01)

Effects of teriparatide in Chinese and Caucasian women with osteoporosis: bridging study on efficacy
by: Xie Z, et al.
Published: (2019-05-01)

Evaluation of Vitamin D isolated or Associated with Teriparatide in Peri-Implant Bone Repair in Tibia of Orchiectomized Rats
by: Pedro Henrique Silva Gomes-Ferreira, et al.
Published: (2023-01-01)

Use of teriparatide in treatment of severe osteoporosis in geriatric practice: a clinical case review
by: Ekaterina N. Dudinskaya, et al.
Published: (2019-12-01)

Is abaloparatide more efficacious on increasing bone mineral density than teriparatide for women with postmenopausal osteoporosis? An updated meta-analysis
by: Pan Hong, et al.
Published: (2023-02-01)

A Case of Resistant Hypocalcemia Treated with Teriparatide
by: Özen Öz Gül, et al.
Published: (2021-03-01)

The cost effectiveness of teriparatide as a first-line treatment for glucocorticoid-induced and postmenopausal osteoporosis patients in Sweden
by: Murphy Daniel R, et al.
Published: (2012-10-01)